Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B

Development of a safe and efficacious vaccine against the HIV/AIDS pandemic remains a major scientific goal. We previously described an HIV/AIDS vaccine based on the modified vaccinia virus Ankara (MVA) expressing HIV-1 gp120 and Gag-Pol-Nef (GPN) of clade B (termed MVA-B), which showed moderate imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez, Patricia, Marín, María Q., Lázaro-Frías, Adrián, Sorzano, Carlos Óscar S., Gómez, Carmen E., Esteban, Mariano, García-Arriaza, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158668/
https://www.ncbi.nlm.nih.gov/pubmed/32041218
http://dx.doi.org/10.3390/vaccines8010070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158668/
https://www.ncbi.nlm.nih.gov/pubmed/32041218
http://dx.doi.org/10.3390/vaccines8010070

Ejemplares similares